You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameNortriptyline
Accession NumberDB00540  (APRD00602)
TypeSmall Molecule
GroupsApproved
DescriptionNortriptyline hydrochloride, the N-demethylated active metabolite of amitriptyline, is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, nortriptyline does not affect mood or arousal, but may cause sedation. In depressed individuals, nortriptyline exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Secondary amine TCAs, such as nortriptyline, are more potent inhibitors of norepinephrine reuptake than tertiary amine TCAs, such as amitriptyline. TCAs also down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine-H1 receptors, α1-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Nortriptyline exerts less anticholinergic and sedative side effects compared to the tertiary amine TCAs, amitriptyline and clomipramine. Nortriptyline may be used to treat depression, chronic pain (unlabeled use), irritable bowel syndrome (unlabeled use), diabetic neuropathy (unlabeled use), post-traumatic stress disorder (unlabeled use), and for migraine prophylaxis (unlabeled use).
Structure
Thumb
Synonyms
10,11-dihydro-N-Methyl-5H-dibenzo[a,D]cycloheptene-delta(5,gamma)-propylamine
3-(10,11-dihydro-5H-Dibenzo[a,D]cyclohepten-5-ylidene)-N-methyl-1-propanamine
Ateben
Avantyl
Aventyl
Demethylamitriptyline
Desmethylamitriptyline
Noritren
Nortriptyline
Psychostyl
Sensaval
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ava-nortriptylinecapsule10 mgoralAvanstra Inc2011-11-282014-08-21Canada
Ava-nortriptylinecapsule25 mgoralAvanstra Inc2011-11-282014-08-21Canada
Aventylcapsule10 mgoralAa Pharma Inc1965-12-31Not applicableCanada
Aventylcapsule25 mgoralAa Pharma Inc1965-12-31Not applicableCanada
Dom-nortriptyline 10mg Capsulescapsule10 mgoralDominion Pharmacal1995-10-012014-09-08Canada
Dom-nortriptyline 25mg Capsulescapsule25 mgoralDominion Pharmacal1995-10-012014-09-08Canada
Gen-nortriptyline Capsules 10mgcapsule10 mgoralGenpharm Ulc1997-09-052009-08-05Canada
Gen-nortriptyline Capsules 25mgcapsule25 mgoralGenpharm Ulc1997-09-052009-08-05Canada
Nortriptylinecapsule25 mgoralPharmel Inc1998-06-042014-09-08Canada
Nortriptylinecapsule10 mgoralPharmel Inc1998-06-042014-09-08Canada
Nortriptyline-10capsule10 mgoralPro Doc Limitee2008-03-072016-07-18Canada
Nortriptyline-25capsule25 mgoralPro Doc Limitee2008-03-072016-07-18Canada
Norventylcapsule25 mgoralValeant Canada Lp Valeant Canada S.E.C.1997-02-042014-07-30Canada
Norventylcapsule10 mgoralValeant Canada Lp Valeant Canada S.E.C.1997-02-042014-07-30Canada
Nu-nortriptyline - Cap 10mgcapsule10 mgoralNu Pharm Inc1996-07-232012-09-04Canada
Nu-nortriptyline - Cap 25mgcapsule25 mgoralNu Pharm Inc1996-07-262012-09-04Canada
Pamelorcapsule10 mg/1oralMallinckrodt, Inc.2010-08-03Not applicableUs
Pamelorcapsule25 mg/1oralMallinckrodt, Inc.2010-08-03Not applicableUs
Pamelorcapsule50 mg/1oralMallinckrodt, Inc.2010-08-03Not applicableUs
Pamelorcapsule75 mg/1oralMallinckrodt, Inc.2010-08-03Not applicableUs
PMS-nortriptylinecapsule25 mgoralPharmascience Inc1996-08-23Not applicableCanada
PMS-nortriptylinecapsule10 mgoralPharmascience Inc1996-08-23Not applicableCanada
Ratio-nortriptylinecapsule10 mgoralRatiopharm Inc Division Of Teva Canada Limited1999-10-212009-07-17Canada
Ratio-nortriptylinecapsule25 mgoralRatiopharm Inc Division Of Teva Canada Limited1999-10-212009-07-17Canada
Teva-nortriptylinecapsule10 mgoralTeva Canada Limited1998-09-10Not applicableCanada
Teva-nortriptylinecapsule25 mgoralTeva Canada Limited1998-09-10Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-nortriptyline - Cap 10mgcapsule10 mgoralApotex Inc1996-09-26Not applicableCanada
Apo-nortriptyline - Cap 25mgcapsule25 mgoralApotex Inc1996-09-26Not applicableCanada
Nortriptyline Hydrochloridecapsule50 mg/1oralClinical Solutions Wholesale1995-04-05Not applicableUs
Nortriptyline Hydrochloridecapsule10 mg/1oralDispensing Solutions, Inc.1995-04-05Not applicableUs
Nortriptyline Hydrochloridecapsule25 mg/1oralA S Medication Solutions1992-07-01Not applicableUs
Nortriptyline Hydrochloridecapsule10 mg/1oralTaro Pharmaceuticals U.S.A., Inc.2000-05-08Not applicableUs
Nortriptyline Hydrochloridecapsule25 mg/1oralMedsource Pharmaceuticals1992-07-01Not applicableUs
Nortriptyline Hydrochloridecapsule25 mg/1oralWatson Laboratories, Inc.1992-07-01Not applicableUs
Nortriptyline Hydrochloridecapsule10 mg/1oralTeva Pharmaceuticals USA Inc1995-04-05Not applicableUs
Nortriptyline Hydrochloridecapsule10 mg/1oralPhysicians Total Care, Inc.2009-06-09Not applicableUs
Nortriptyline Hydrochloridecapsule25 mg/1oralProficient Rx LP1992-07-01Not applicableUs
Nortriptyline Hydrochloridecapsule50 mg/1oralPreferred Pharmaceuticals, Inc.2012-03-05Not applicableUs
Nortriptyline Hydrochloridecapsule25 mg/1oralREMEDYREPACK INC.2011-05-13Not applicableUs
Nortriptyline Hydrochloridecapsule75 mg/1oralRebel Distributors Corp1992-03-30Not applicableUs
Nortriptyline Hydrochloridecapsule50 mg/1oralREMEDYREPACK INC.2014-06-11Not applicableUs
Nortriptyline Hydrochloridecapsule75 mg/1oralREMEDYREPACK INC.2011-06-20Not applicableUs
Nortriptyline Hydrochloridecapsule25 mg/1oralSTAT Rx USA LLC1992-07-01Not applicableUs
Nortriptyline Hydrochloridecapsule50 mg/1oralDIRECT RX2014-01-01Not applicableUs
Nortriptyline Hydrochloridecapsule50 mg/1oralAmerican Health Packaging2015-03-31Not applicableUs
Nortriptyline Hydrochloridecapsule25 mg/1oralUnit Dose Services1992-07-01Not applicableUs
Nortriptyline Hydrochloridecapsule75 mg/1oralAidarex Pharmaceuticals LLC1995-04-05Not applicableUs
Nortriptyline Hydrochloridesolution10 mg/5mLoralPharmaceutical Associates, Inc.2000-08-23Not applicableUs
Nortriptyline Hydrochloridecapsule10 mg/1oralClinical Solutions Wholesale1995-04-05Not applicableUs
Nortriptyline Hydrochloridecapsule10 mg/1oralbryant ranch prepack1995-04-05Not applicableUs
Nortriptyline Hydrochloridecapsule50 mg/1oralWatson Laboratories, Inc.1992-07-01Not applicableUs
Nortriptyline Hydrochloridecapsule50 mg/1oralSt Marys Medical Park Pharmacy2014-05-23Not applicableUs
Nortriptyline Hydrochloridecapsule25 mg/1oralAphena Pharma Solutions Tennessee, Llc1995-04-06Not applicableUs
Nortriptyline Hydrochloridecapsule25 mg/1oralTaro Pharmaceuticals U.S.A., Inc.2000-05-08Not applicableUs
Nortriptyline Hydrochloridecapsule75 mg/1oralMedsource Pharmaceuticals2000-05-08Not applicableUs
Nortriptyline Hydrochloridecapsule25 mg/1oralTeva Pharmaceuticals USA Inc1995-04-06Not applicableUs
Nortriptyline Hydrochloridecapsule25 mg/1oralCardinal Health2011-05-19Not applicableUs
Nortriptyline Hydrochloridecapsule75 mg/1oralProficient Rx LP1992-07-01Not applicableUs
Nortriptyline Hydrochloridecapsule25 mg/1oralPreferred Pharmaceuticals, Inc.2012-03-05Not applicableUs
Nortriptyline Hydrochloridecapsule25 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-01-27Not applicableUs
Nortriptyline Hydrochloridecapsule25 mg/1oralAidarex Pharmaceuticals LLC1995-04-06Not applicableUs
Nortriptyline Hydrochloridecapsule25 mg/1oralPhysicians Total Care, Inc.1993-09-10Not applicableUs
Nortriptyline Hydrochloridecapsule50 mg/1oralREMEDYREPACK INC.2013-03-01Not applicableUs
Nortriptyline Hydrochloridecapsule10 mg/1oralRebel Distributors Corp1992-03-30Not applicableUs
Nortriptyline Hydrochloridecapsule10 mg/1oralDIRECT RX2015-01-01Not applicableUs
Nortriptyline Hydrochloridecapsule50 mg/1oralPreferred Pharmaceuticals, Inc.2015-05-07Not applicableUs
Nortriptyline Hydrochloridecapsule50 mg/1oralUnit Dose Services1992-07-01Not applicableUs
Nortriptyline Hydrochloridecapsule10 mg/1oralLake Erie Medical DBA Quality Care Products LLC1992-07-01Not applicableUs
Nortriptyline Hydrochloridecapsule10 mg/1oralKAISER FOUNDATION HOSPITALS2014-06-17Not applicableUs
Nortriptyline Hydrochloridecapsule25 mg/1oralClinical Solutions Wholesale1995-04-06Not applicableUs
Nortriptyline Hydrochloridecapsule50 mg/1oralbryant ranch prepack2010-11-03Not applicableUs
Nortriptyline Hydrochloridecapsule10 mg/1oralREMEDYREPACK INC.2010-11-16Not applicableUs
Nortriptyline Hydrochloridecapsule75 mg/1oralWatson Laboratories, Inc.1992-07-01Not applicableUs
Nortriptyline Hydrochloridecapsule75 mg/1oralREMEDYREPACK INC.2014-08-29Not applicableUs
Nortriptyline Hydrochloridecapsule10 mg/1oralAmerican Health Packaging1992-07-01Not applicableUs
Nortriptyline Hydrochloridecapsule50 mg/1oralTaro Pharmaceuticals U.S.A., Inc.2000-05-08Not applicableUs
Nortriptyline Hydrochloridecapsule10 mg/1oralAidarex Pharmaceuticals LLC1992-07-01Not applicableUs
Nortriptyline Hydrochloridecapsule50 mg/1oralTeva Pharmaceuticals USA Inc1995-04-05Not applicableUs
Nortriptyline Hydrochloridecapsule25 mg/1oralPd Rx Pharmaceuticals, Inc.1992-07-01Not applicableUs
Nortriptyline Hydrochloridecapsule10 mg/1oralProficient Rx LP1992-07-01Not applicableUs
Nortriptyline Hydrochloridecapsule25 mg/1oralPreferred Pharmaceuticals, Inc.2015-04-13Not applicableUs
Nortriptyline Hydrochloridecapsule10 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-02-08Not applicableUs
Nortriptyline Hydrochloridecapsule50 mg/1oralPhysicians Total Care, Inc.2004-02-25Not applicableUs
Nortriptyline Hydrochloridecapsule10 mg/1oralREMEDYREPACK INC.2011-09-21Not applicableUs
Nortriptyline Hydrochloridecapsule25 mg/1oralRebel Distributors Corp1992-03-30Not applicableUs
Nortriptyline Hydrochloridecapsule50 mg/1oralDIRECT RX2014-01-01Not applicableUs
Nortriptyline Hydrochloridecapsule10 mg/1oralPreferred Pharmaceuticals, Inc.2012-03-05Not applicableUs
Nortriptyline Hydrochloridecapsule10 mg/1oralUnit Dose Services1992-07-01Not applicableUs
Nortriptyline Hydrochloridecapsule25 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC1992-07-01Not applicableUs
Nortriptyline Hydrochloridecapsule10 mg/1oralWatson Laboratories, Inc.1992-07-01Not applicableUs
Nortriptyline Hydrochloridecapsule75 mg/1oralClinical Solutions Wholesale1995-04-05Not applicableUs
Nortriptyline Hydrochloridecapsule75 mg/1oralbryant ranch prepack1992-07-01Not applicableUs
Nortriptyline Hydrochloridecapsule10 mg/1oralA S Medication Solutions2000-05-08Not applicableUs
Nortriptyline Hydrochloridecapsule25 mg/1oralREMEDYREPACK INC.2011-03-30Not applicableUs
Nortriptyline Hydrochloridecapsule10 mg/1oralBlenheim Pharmacal, Inc.2013-11-14Not applicableUs
Nortriptyline Hydrochloridecapsule25 mg/1oralDIRECT RX2015-01-01Not applicableUs
Nortriptyline Hydrochloridecapsule25 mg/1oralAmerican Health Packaging1992-07-01Not applicableUs
Nortriptyline Hydrochloridecapsule75 mg/1oralTaro Pharmaceuticals U.S.A., Inc.2000-05-08Not applicableUs
Nortriptyline Hydrochloridecapsule50 mg/1oralAidarex Pharmaceuticals LLC1995-04-05Not applicableUs
Nortriptyline Hydrochloridecapsule75 mg/1oralTeva Pharmaceuticals USA Inc1995-04-05Not applicableUs
Nortriptyline Hydrochloridecapsule10 mg/1oralPd Rx Pharmaceuticals, Inc.1992-07-01Not applicableUs
Nortriptyline Hydrochloridecapsule25 mg/1oralbryant ranch prepack1992-07-01Not applicableUs
Nortriptyline Hydrochloridecapsule25 mg/1oralCarilion Materials Management1995-04-06Not applicableUs
Nortriptyline Hydrochloridecapsule50 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-12-05Not applicableUs
Nortriptyline Hydrochloridecapsule75 mg/1oralPhysicians Total Care, Inc.2008-11-11Not applicableUs
Nortriptyline Hydrochloridecapsule50 mg/1oralREMEDYREPACK INC.2011-12-12Not applicableUs
Nortriptyline Hydrochloridecapsule50 mg/1oralRebel Distributors Corp1992-03-30Not applicableUs
Nortriptyline Hydrochloridecapsule50 mg/1oralProficient Rx LP1992-07-01Not applicableUs
Nortriptyline Hydrochloridecapsule25 mg/1oralPreferred Pharmaceuticals Inc.2015-08-17Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AllegronNot Available
NoritrenNot Available
NorpressNot Available
NortrilenNot Available
SensovalNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Nortriptyline Hydrochloride
Thumb
  • InChI Key: SHAYBENGXDALFF-UHFFFAOYSA-N
  • Monoisotopic Mass: 299.144077416
  • Average Mass: 299.838
DBSALT000641
Categories
UNIIBL03SY4LXB
CAS number72-69-5
WeightAverage: 263.3767
Monoisotopic: 263.167399677
Chemical FormulaC19H21N
InChI KeyInChIKey=PHVGLTMQBUFIQQ-UHFFFAOYSA-N
InChI
InChI=1S/C19H21N/c1-20-14-6-11-19-17-9-4-2-7-15(17)12-13-16-8-3-5-10-18(16)19/h2-5,7-11,20H,6,12-14H2,1H3
IUPAC Name
methyl(3-{tricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,11,13-hexaen-2-ylidene}propyl)amine
SMILES
CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dibenzocycloheptenes. These are compounds containing a dibenzocycloheptene moiety, which consists of two benzene connected by a cycloheptene ring.
KingdomOrganic compounds
Super ClassBenzenoids
ClassDibenzocycloheptenes
Sub ClassNot Available
Direct ParentDibenzocycloheptenes
Alternative Parents
Substituents
  • Dibenzocycloheptene
  • Secondary amine
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Amine
  • Aromatic homopolycyclic compound
Molecular FrameworkAromatic homopolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of depression, chronic pain, irritable bowel syndrome, sleep disorders, diabetic neuropathy, agitation and insomnia, and migraine prophylaxis.
PharmacodynamicsSimilar to protriptyline, nortriptyline is a tricyclic antidepressant of the dibenzocycloheptene type and is the active metabolite of amitriptyline.
Mechanism of actionIt is believed that nortriptyline either inhibits the reuptake of the neurotransmitter serotonin at the neuronal membrane or acts at beta-adrenergic receptors. Tricyclic antidepressants do not inhibit monoamine oxidase nor do they affect dopamine reuptake.
Related Articles
AbsorptionWell absorbed from the GI tract. Peak plasma concentrations occur 7-8.5 hours following oral administration.
Volume of distributionNot Available
Protein bindingHighly protein-bound in plasma and tissues.
Metabolism

Undergoes hepatic metabolism via the same pathway as other TCAs.

SubstrateEnzymesProduct
Nortriptyline
E-10-HydroxynortriptylineDetails
Nortriptyline
DesmethylnortriptylineDetails
E-10-Hydroxynortriptyline
Not Available
E-10-HydroxydesmethylnortriptylineDetails
Desmethylnortriptyline
E-10-HydroxydesmethylnortriptylineDetails
Route of eliminationApproximately one-third of a single orally administered dose is excreted in urine within 24 hours. Small amounts are excreted in feces via biliary elimination.
Half life16 to 90+ hours
ClearanceNot Available
ToxicitySymptoms of overdose include cardiac dysrhythmias, severe hypotension, shock, congestive heart failure, pulmonary edema, convulsions, and CNS depression, including coma. Changes in the electrocardiogram, particularly in QRS axis or width, are clinically significant indicators of tricyclic antidepressant toxicity. Side effects include: sedation, hypotension, blurred vision, dry mouth, constipation, urinary retention, postural hypotension, tachycardia, hypertension, ECG changes, heart failure, impaired memory and delirium, and precipitation of hypomanic or manic episodes in bipolar depression. Withdrawal symptoms include gastrointestinal disturbances, anxiety, and insomnia.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Cytochrome P450 2D6
Gene symbol: CYP2D6
UniProt: P10635
rs3892097 CYP2D6*4A AllelePoor drug metabolizer, lower dose requirements, higher risk for adverse side effects18070221
SNP Mediated Adverse Drug Reactions
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeAdverse ReactionReference(s)
Multidrug resistance protein 1
Gene symbol: ABCB1
UniProt: P08183
rs1045642 Not AvailableT Allele, homozygousPostural hypotension12082591
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9478
Caco-2 permeable+0.774
P-glycoprotein substrateSubstrate0.7863
P-glycoprotein inhibitor IInhibitor0.8876
P-glycoprotein inhibitor IIInhibitor0.5376
Renal organic cation transporterInhibitor0.6903
CYP450 2C9 substrateNon-substrate0.7508
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.5593
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.7665
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5194
Ames testNon AMES toxic0.5315
CarcinogenicityNon-carcinogens0.9182
BiodegradationReady biodegradable0.5
Rat acute toxicity2.7513 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5809
hERG inhibition (predictor II)Inhibitor0.7763
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Eli lilly and co
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Taro pharmaceuticals inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Tyco healthcare group lp
  • Ranbaxy pharmaceuticals inc
  • Pharmaceutical assoc inc
  • Taro pharmaceutical industries ltd
Packagers
Dosage forms
FormRouteStrength
Capsuleoral10 mg
Capsuleoral25 mg
Capsuleoral10 mg/1
Capsuleoral25 mg/1
Capsuleoral50 mg/1
Capsuleoral75 mg/1
Solutionoral10 mg/5mL
Prices
Unit descriptionCostUnit
Pamelor 30 10 mg capsule Bottle750.05USD bottle
Pamelor 30 25 mg capsule Bottle750.05USD bottle
Pamelor 30 50 mg capsule Bottle750.05USD bottle
Pamelor 10 mg/5ml Solution 480ml Bottle325.97USD bottle
Pamelor 10 mg capsule24.04USD capsule
Pamelor 25 mg capsule24.04USD capsule
Pamelor 50 mg capsule24.04USD capsule
Pamelor 75 mg capsule19.34USD capsule
Nortriptyline hcl powder11.09USD g
Nortriptyline hcl 75 mg capsule1.33USD capsule
Nortriptyline hcl 50 mg capsule0.94USD capsule
Nortriptyline hcl 25 mg capsule0.6USD capsule
Aventyl 25 mg Capsule0.48USD capsule
Nortriptyline HCl 10 mg/5ml Solution0.4USD ml
Nortriptyline hcl 10 mg capsule0.28USD capsule
Apo-Nortriptyline 25 mg Capsule0.27USD capsule
Novo-Nortriptyline 25 mg Capsule0.27USD capsule
Nu-Nortriptyline 25 mg Capsule0.27USD capsule
Pms-Nortriptyline 25 mg Capsule0.27USD capsule
Aventyl 10 mg Capsule0.24USD capsule
Apo-Nortriptyline 10 mg Capsule0.13USD capsule
Novo-Nortriptyline 10 mg Capsule0.13USD capsule
Nu-Nortriptyline 10 mg Capsule0.13USD capsule
Pms-Nortriptyline 10 mg Capsule0.13USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point213-215 °CNot Available
logP4.51BRODIN,A (1974)
pKa10.1SANGSTER (2004)
Predicted Properties
PropertyValueSource
Water Solubility0.000874 mg/mLALOGPS
logP4.65ALOGPS
logP4.43ChemAxon
logS-5.5ALOGPS
pKa (Strongest Basic)10.47ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area12.03 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity96.21 m3·mol-1ChemAxon
Polarizability31.87 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (7.76 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0006-9230000000-15f73e5232a0e230f41bView in MoNA
References
Synthesis Reference

Abraham Nudelman, “ACID ADDITION SALT OF A NORTRIPTYLINE-GABA CONJUGATE AND A PROCESS OF PREPARING SAME.” U.S. Patent US20130184347, issued July 18, 2013.

US20130184347
General References
  1. Prochazka AV, Weaver MJ, Keller RT, Fryer GE, Licari PA, Lofaso D: A randomized trial of nortriptyline for smoking cessation. Arch Intern Med. 1998 Oct 12;158(18):2035-9. [PubMed:9778204 ]
External Links
ATC CodesN06AA10
AHFS Codes
  • 28:16.04.28
PDB EntriesNot Available
FDA labelDownload (420 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe serum concentration of Nortriptyline can be increased when it is combined with 1,10-Phenanthroline.
3,4-DichloroisocoumarinThe serum concentration of Nortriptyline can be increased when it is combined with 3,4-Dichloroisocoumarin.
3,4-MethylenedioxyamphetamineNortriptyline may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetamineNortriptyline may increase the stimulatory activities of 3,4-Methylenedioxymethamphetamine.
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe serum concentration of Nortriptyline can be increased when it is combined with 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE.
4-MethoxyamphetamineThe therapeutic efficacy of 4-Methoxyamphetamine can be decreased when used in combination with Nortriptyline.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Nortriptyline.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the serotonergic activities of Nortriptyline.
AbirateroneThe serum concentration of Nortriptyline can be increased when it is combined with Abiraterone.
AcenocoumarolNortriptyline may increase the anticoagulant activities of Acenocoumarol.
AcepromazineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Aceprometazine.
AcetophenazineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Acetophenazine.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Nortriptyline.
AgmatineThe therapeutic efficacy of Agmatine can be decreased when used in combination with Nortriptyline.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Nortriptyline.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Nortriptyline.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Nortriptyline.
AlmotriptanThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Almotriptan.
AlogliptinThe serum concentration of Nortriptyline can be increased when it is combined with Alogliptin.
Alpha-1-proteinase inhibitorThe serum concentration of Nortriptyline can be increased when it is combined with Alpha-1-proteinase inhibitor.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Nortriptyline.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Nortriptyline.
AltretamineAltretamine may increase the orthostatic hypotensive activities of Nortriptyline.
AmiodaroneNortriptyline may increase the QTc-prolonging activities of Amiodarone.
AmiodaroneThe metabolism of Nortriptyline can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Nortriptyline.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Nortriptyline.
AmoxapineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Amperozide.
AmphetamineNortriptyline may increase the stimulatory activities of Amphetamine.
AmprenavirThe serum concentration of Nortriptyline can be increased when it is combined with Amprenavir.
AnagrelideNortriptyline may increase the QTc-prolonging activities of Anagrelide.
Antithrombin III humanThe serum concentration of Nortriptyline can be increased when it is combined with Antithrombin III human.
ApixabanThe serum concentration of Nortriptyline can be increased when it is combined with Apixaban.
ApomorphineThe therapeutic efficacy of Apomorphine can be decreased when used in combination with Nortriptyline.
ApraclonidineThe therapeutic efficacy of Apraclonidine can be decreased when used in combination with Nortriptyline.
AprepitantThe serum concentration of Nortriptyline can be increased when it is combined with Aprepitant.
AprotininThe serum concentration of Nortriptyline can be increased when it is combined with Aprotinin.
ArbutamineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Arbutamine.
ArformoterolThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Arformoterol.
ArgatrobanThe serum concentration of Nortriptyline can be increased when it is combined with Argatroban.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Nortriptyline.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Nortriptyline.
ArmodafinilThe metabolism of Nortriptyline can be decreased when combined with Armodafinil.
Arsenic trioxideNortriptyline may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherNortriptyline may increase the QTc-prolonging activities of Artemether.
ArtemetherThe metabolism of Nortriptyline can be decreased when combined with Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Nortriptyline.
AsenapineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Asenapine.
AsunaprevirThe serum concentration of Nortriptyline can be increased when it is combined with Asunaprevir.
AtazanavirThe serum concentration of Nortriptyline can be increased when it is combined with Atazanavir.
AtomoxetineThe metabolism of Nortriptyline can be decreased when combined with Atomoxetine.
AzaperoneThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Azaperone.
AzelastineNortriptyline may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Nortriptyline.
AzithromycinNortriptyline may increase the QTc-prolonging activities of Azithromycin.
AzithromycinThe metabolism of Nortriptyline can be decreased when combined with Azithromycin.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Nortriptyline.
BambuterolThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Bambuterol.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Nortriptyline.
BatimastatThe serum concentration of Nortriptyline can be increased when it is combined with Batimastat.
BedaquilineNortriptyline may increase the QTc-prolonging activities of Bedaquiline.
BenazeprilThe serum concentration of Nortriptyline can be increased when it is combined with Benazepril.
BenmoxinBenmoxin may increase the serotonergic activities of Nortriptyline.
BenzamidineThe serum concentration of Nortriptyline can be increased when it is combined with Benzamidine.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Nortriptyline.
BenzphetamineNortriptyline may increase the stimulatory activities of Benzphetamine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Nortriptyline.
BetaxololThe metabolism of Nortriptyline can be decreased when combined with Betaxolol.
BethanidineThe therapeutic efficacy of Bethanidine can be decreased when used in combination with Nortriptyline.
BexaroteneThe serum concentration of Nortriptyline can be decreased when it is combined with Bexarotene.
BifeprunoxThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Bifeprunox.
BivalirudinThe serum concentration of Nortriptyline can be increased when it is combined with Bivalirudin.
BoceprevirThe serum concentration of Nortriptyline can be increased when it is combined with Boceprevir.
BortezomibThe metabolism of Nortriptyline can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Nortriptyline can be decreased when it is combined with Bosentan.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.
BrimonidineThe therapeutic efficacy of Brimonidine can be decreased when used in combination with Nortriptyline.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Nortriptyline.
BromocriptineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Nortriptyline.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Nortriptyline.
BrompheniramineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Nortriptyline.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Nortriptyline.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Nortriptyline.
BupropionThe metabolism of Nortriptyline can be decreased when combined with Bupropion.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Nortriptyline.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Nortriptyline.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Nortriptyline.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Nortriptyline.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Nortriptyline.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Nortriptyline.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Nortriptyline.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Nortriptyline.
CaffeineThe metabolism of Nortriptyline can be decreased when combined with Caffeine.
CandoxatrilThe serum concentration of Nortriptyline can be increased when it is combined with Candoxatril.
CapecitabineThe metabolism of Nortriptyline can be decreased when combined with Capecitabine.
CaptoprilThe serum concentration of Nortriptyline can be increased when it is combined with Captopril.
CarbamazepineThe metabolism of Nortriptyline can be increased when combined with Carbamazepine.
CarbamazepineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Carbamazepine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Nortriptyline.
CariprazineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Cariprazine.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Nortriptyline.
CaroxazoneCaroxazone may increase the serotonergic activities of Nortriptyline.
CelecoxibThe metabolism of Nortriptyline can be decreased when combined with Celecoxib.
CeliprololThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Celiprolol.
CeritinibThe serum concentration of Nortriptyline can be increased when it is combined with Ceritinib.
CeritinibNortriptyline may increase the QTc-prolonging activities of Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Nortriptyline.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Nortriptyline.
ChloramphenicolThe metabolism of Nortriptyline can be decreased when combined with Chloramphenicol.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Nortriptyline.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Nortriptyline.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Nortriptyline.
ChloroquineNortriptyline may increase the QTc-prolonging activities of Chloroquine.
ChloroquineThe metabolism of Nortriptyline can be decreased when combined with Chloroquine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Chlorphenamine.
ChlorphentermineNortriptyline may increase the stimulatory activities of Chlorphentermine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Chlorpromazine.
ChlorpromazineThe metabolism of Nortriptyline can be decreased when combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Chlorprothixene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Nortriptyline.
CholecalciferolThe metabolism of Nortriptyline can be decreased when combined with Cholecalciferol.
ChymostatinThe serum concentration of Nortriptyline can be increased when it is combined with Chymostatin.
CilastatinThe serum concentration of Nortriptyline can be increased when it is combined with Cilastatin.
CilazaprilThe serum concentration of Nortriptyline can be increased when it is combined with Cilazapril.
CimetidineThe metabolism of Nortriptyline can be decreased when combined with Cimetidine.
CinacalcetThe serum concentration of Nortriptyline can be increased when it is combined with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Nortriptyline.
CiprofloxacinNortriptyline may increase the QTc-prolonging activities of Ciprofloxacin.
CirazolineNortriptyline may increase the vasopressor activities of Cirazoline.
CisaprideNortriptyline may increase the QTc-prolonging activities of Cisapride.
CitalopramThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Citalopram.
CitalopramThe metabolism of Nortriptyline can be decreased when combined with Citalopram.
ClarithromycinNortriptyline may increase the QTc-prolonging activities of Clarithromycin.
ClarithromycinThe metabolism of Nortriptyline can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Nortriptyline can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Clemastine.
ClenbuterolThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Clenbuterol.
ClidiniumThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Clidinium.
ClobazamThe metabolism of Nortriptyline can be decreased when combined with Clobazam.
ClobazamThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Nortriptyline.
ClomipramineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Clomipramine.
ClomipramineThe metabolism of Nortriptyline can be decreased when combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Clonazepam.
ClonidineThe therapeutic efficacy of Clonidine can be decreased when used in combination with Nortriptyline.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Nortriptyline.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Nortriptyline.
ClotrimazoleThe metabolism of Nortriptyline can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Clozapine.
ClozapineThe metabolism of Nortriptyline can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Nortriptyline can be increased when it is combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Nortriptyline.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Nortriptyline.
ConivaptanThe serum concentration of Nortriptyline can be increased when it is combined with Conivaptan.
CrizotinibNortriptyline may increase the QTc-prolonging activities of Crizotinib.
CrizotinibThe metabolism of Nortriptyline can be decreased when combined with Crizotinib.
CyamemazineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Cyamemazine.
CyclizineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Nortriptyline.
CyclosporineThe metabolism of Nortriptyline can be decreased when combined with Cyclosporine.
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Nortriptyline.
Cyproterone acetateThe serum concentration of Nortriptyline can be decreased when it is combined with Cyproterone acetate.
Dabigatran etexilateThe serum concentration of Nortriptyline can be increased when it is combined with Dabigatran etexilate.
DabrafenibThe serum concentration of Nortriptyline can be decreased when it is combined with Dabrafenib.
DantroleneThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Dapiprazole.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Nortriptyline.
DarifenacinThe metabolism of Nortriptyline can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Nortriptyline can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Nortriptyline can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Nortriptyline can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Nortriptyline can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Nortriptyline.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Nortriptyline.
DesipramineThe metabolism of Nortriptyline can be decreased when combined with Desipramine.
DesipramineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Desloratadine.
DesmopressinThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Desmopressin.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Desvenlafaxine.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Nortriptyline.
DexamethasoneThe serum concentration of Nortriptyline can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Nortriptyline.
DexmedetomidineThe therapeutic efficacy of Dexmedetomidine can be decreased when used in combination with Nortriptyline.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Nortriptyline.
DexmethylphenidateThe risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Nortriptyline.
DextroamphetamineNortriptyline may increase the stimulatory activities of Dextroamphetamine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Nortriptyline.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Nortriptyline.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Nortriptyline.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Nortriptyline.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Nortriptyline.
DicoumarolNortriptyline may increase the anticoagulant activities of Dicoumarol.
DifenoxinThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Nortriptyline.
DihydroergotamineThe therapeutic efficacy of Dihydroergotamine can be decreased when used in combination with Nortriptyline.
DihydroergotamineThe metabolism of Nortriptyline can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Nortriptyline.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Nortriptyline.
DiltiazemThe metabolism of Nortriptyline can be decreased when combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Dimenhydrinate.
DiphenhydramineThe metabolism of Nortriptyline can be decreased when combined with Diphenhydramine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Nortriptyline.
DipivefrinThe therapeutic efficacy of Dipivefrin can be decreased when used in combination with Nortriptyline.
DisopyramideNortriptyline may increase the QTc-prolonging activities of Disopyramide.
DobutamineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Dobutamine.
DofetilideNortriptyline may increase the QTc-prolonging activities of Dofetilide.
DolasetronNortriptyline may increase the QTc-prolonging activities of Dolasetron.
DolasetronDolasetron may increase the serotonergic activities of Nortriptyline.
DomperidoneNortriptyline may increase the QTc-prolonging activities of Domperidone.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Nortriptyline.
DoxepinThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Doxepin.
DoxycyclineThe metabolism of Nortriptyline can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.
DoxylamineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Nortriptyline.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.
DronedaroneThe metabolism of Nortriptyline can be decreased when combined with Dronedarone.
DronedaroneNortriptyline may increase the QTc-prolonging activities of Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Droperidol.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Nortriptyline.
DroxidopaThe therapeutic efficacy of Droxidopa can be decreased when used in combination with Nortriptyline.
DuloxetineThe metabolism of Nortriptyline can be decreased when combined with Duloxetine.
DuloxetineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Duloxetine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Nortriptyline.
EcabetThe serum concentration of Nortriptyline can be increased when it is combined with Ecabet.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Nortriptyline.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Nortriptyline.
EdoxabanThe serum concentration of Nortriptyline can be increased when it is combined with Edoxaban.
EfavirenzThe serum concentration of Nortriptyline can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Efavirenz.
ElafinThe serum concentration of Nortriptyline can be increased when it is combined with Elafin.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Nortriptyline.
EliglustatNortriptyline may increase the QTc-prolonging activities of Eliglustat.
EliglustatThe metabolism of Nortriptyline can be decreased when combined with Eliglustat.
EnalaprilThe serum concentration of Nortriptyline can be increased when it is combined with Enalapril.
EnalaprilatThe serum concentration of Nortriptyline can be increased when it is combined with Enalaprilat.
EnalkirenThe serum concentration of Nortriptyline can be increased when it is combined with Enalkiren.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Nortriptyline.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Nortriptyline.
EnzalutamideThe serum concentration of Nortriptyline can be decreased when it is combined with Enzalutamide.
EphedraThe therapeutic efficacy of Ephedra can be decreased when used in combination with Nortriptyline.
EpinephrineThe therapeutic efficacy of Epinephrine can be decreased when used in combination with Nortriptyline.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Ergoloid mesylate.
ErgonovineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Ergonovine.
ErgotamineNortriptyline may increase the vasopressor activities of Ergotamine.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Nortriptyline.
ErythromycinNortriptyline may increase the QTc-prolonging activities of Erythromycin.
ErythromycinThe metabolism of Nortriptyline can be decreased when combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Nortriptyline can be decreased when it is combined with Eslicarbazepine acetate.
EsomeprazoleThe metabolism of Nortriptyline can be decreased when combined with Esomeprazole.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Nortriptyline.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Nortriptyline.
EthanolNortriptyline may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Nortriptyline.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Nortriptyline.
EthosuximideThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Ethotoin.
Ethyl biscoumacetateNortriptyline may increase the anticoagulant activities of Ethyl biscoumacetate.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Nortriptyline.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Nortriptyline.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Nortriptyline.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Nortriptyline.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Nortriptyline.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Nortriptyline.
EtomidateThe therapeutic efficacy of Etomidate can be decreased when used in combination with Nortriptyline.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Nortriptyline.
EtoperidoneThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Nortriptyline.
EtravirineThe serum concentration of Nortriptyline can be decreased when it is combined with Etravirine.
EzogabineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Fenfluramine.
FenoterolThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Fenoterol.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Nortriptyline.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Nortriptyline.
FexofenadineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Fexofenadine.
FlecainideNortriptyline may increase the QTc-prolonging activities of Flecainide.
FlibanserinThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Flibanserin.
FloxuridineThe metabolism of Nortriptyline can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Nortriptyline can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Nortriptyline.
FlunarizineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Nortriptyline.
FluorouracilThe metabolism of Nortriptyline can be decreased when combined with Fluorouracil.
FluoxetineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Fluoxetine.
FluoxetineThe metabolism of Nortriptyline can be decreased when combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Fluphenazine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Nortriptyline.
FluspirileneThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Fluticasone Propionate.
FluvastatinThe metabolism of Nortriptyline can be decreased when combined with Fluvastatin.
FluvoxamineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Fluvoxamine.
FluvoxamineThe metabolism of Nortriptyline can be decreased when combined with Fluvoxamine.
FormoterolThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Formoterol.
FosamprenavirThe serum concentration of Nortriptyline can be increased when it is combined with Fosamprenavir.
FosaprepitantThe serum concentration of Nortriptyline can be increased when it is combined with Fosaprepitant.
FosinoprilThe serum concentration of Nortriptyline can be increased when it is combined with Fosinopril.
FosphenytoinThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Nortriptyline.
FrovatriptanThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Frovatriptan.
FurazolidoneFurazolidone may increase the serotonergic activities of Nortriptyline.
Fusidic AcidThe serum concentration of Nortriptyline can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Nortriptyline.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Nortriptyline is combined with gabapentin enacarbil.
Gadobenic acidNortriptyline may increase the QTc-prolonging activities of Gadobenic acid.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Nortriptyline.
GeldanamycinThe serum concentration of Nortriptyline can be increased when it is combined with Geldanamycin.
GemfibrozilThe metabolism of Nortriptyline can be decreased when combined with Gemfibrozil.
GemifloxacinNortriptyline may increase the QTc-prolonging activities of Gemifloxacin.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Nortriptyline.
GM6001The serum concentration of Nortriptyline can be increased when it is combined with GM6001.
GoserelinNortriptyline may increase the QTc-prolonging activities of Goserelin.
GranisetronNortriptyline may increase the QTc-prolonging activities of Granisetron.
GranisetronGranisetron may increase the serotonergic activities of Nortriptyline.
GuanabenzThe therapeutic efficacy of Guanabenz can be decreased when used in combination with Nortriptyline.
GuanfacineThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Nortriptyline.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Nortriptyline.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Nortriptyline.
HaloperidolThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Haloperidol.
HaloperidolThe metabolism of Nortriptyline can be decreased when combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Nortriptyline.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Nortriptyline.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Nortriptyline.
HirulogThe serum concentration of Nortriptyline can be increased when it is combined with Hirulog.
HydracarbazineHydracarbazine may increase the serotonergic activities of Nortriptyline.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Nortriptyline.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Nortriptyline.
Hydroxyamphetamine hydrobromideNortriptyline may increase the stimulatory activities of Hydroxyamphetamine hydrobromide.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.
HydroxyzineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Hydroxyzine.
IbutilideNortriptyline may increase the QTc-prolonging activities of Ibutilide.
IdelalisibThe serum concentration of Nortriptyline can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Iloperidone.
ImatinibThe metabolism of Nortriptyline can be decreased when combined with Imatinib.
ImipramineThe metabolism of Nortriptyline can be decreased when combined with Imipramine.
ImipramineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Imipramine.
IndacaterolThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Indacaterol.
IndalpineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Indalpine.
IndinavirThe serum concentration of Nortriptyline can be increased when it is combined with Indinavir.
IproclozideIproclozide may increase the serotonergic activities of Nortriptyline.
IproniazidIproniazid may increase the serotonergic activities of Nortriptyline.
IrbesartanThe metabolism of Nortriptyline can be decreased when combined with Irbesartan.
IsavuconazoniumThe metabolism of Nortriptyline can be decreased when combined with Isavuconazonium.
IsocarboxazidIsocarboxazid may increase the serotonergic activities of Nortriptyline.
IsocarboxazidThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Isocarboxazid.
IsoetarineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Isoetarine.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Nortriptyline.
IsoflurophateThe serum concentration of Nortriptyline can be increased when it is combined with Isoflurophate.
IsoniazidThe metabolism of Nortriptyline can be decreased when combined with Isoniazid.
IsoprenalineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Isoprenaline.
IsradipineThe metabolism of Nortriptyline can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Nortriptyline can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Nortriptyline can be increased when it is combined with Ivacaftor.
IxazomibThe serum concentration of Nortriptyline can be increased when it is combined with Ixazomib.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Nortriptyline.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Nortriptyline.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Nortriptyline.
KetoconazoleThe metabolism of Nortriptyline can be decreased when combined with Ketoconazole.
LamotrigineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Lamotrigine.
LeflunomideThe metabolism of Nortriptyline can be decreased when combined with Leflunomide.
LenvatinibNortriptyline may increase the QTc-prolonging activities of Lenvatinib.
LepirudinThe serum concentration of Nortriptyline can be increased when it is combined with Lepirudin.
LeuprolideNortriptyline may increase the QTc-prolonging activities of Leuprolide.
LevetiracetamThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Nortriptyline.
LevocabastineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Levodopa.
LevofloxacinNortriptyline may increase the QTc-prolonging activities of Levofloxacin.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Nortriptyline.
LevomilnacipranThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Nortriptyline.
LevothyroxineLevothyroxine may increase the arrhythmogenic activities of Nortriptyline.
LidocaineThe metabolism of Nortriptyline can be decreased when combined with Lidocaine.
LidocaineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Lidocaine.
LinagliptinThe serum concentration of Nortriptyline can be increased when it is combined with Linagliptin.
LinezolidLinezolid may increase the serotonergic activities of Nortriptyline.
LinezolidThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Linezolid.
LiothyronineLiothyronine may increase the arrhythmogenic activities of Nortriptyline.
LiotrixLiotrix may increase the arrhythmogenic activities of Nortriptyline.
LisdexamfetamineNortriptyline may increase the stimulatory activities of Lisdexamfetamine.
LisinoprilThe serum concentration of Nortriptyline can be increased when it is combined with Lisinopril.
LithiumThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Nortriptyline.
LofexidineThe therapeutic efficacy of Lofexidine can be decreased when used in combination with Nortriptyline.
LopinavirThe serum concentration of Nortriptyline can be increased when it is combined with Lopinavir.
LopinavirNortriptyline may increase the QTc-prolonging activities of Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Nortriptyline.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Nortriptyline.
LorcaserinThe metabolism of Nortriptyline can be decreased when combined with Lorcaserin.
LorcaserinThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Lorcaserin.
LosartanThe metabolism of Nortriptyline can be decreased when combined with Losartan.
LovastatinThe metabolism of Nortriptyline can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Loxapine.
Lu AA21004The risk or severity of adverse effects can be increased when Nortriptyline is combined with Lu AA21004.
LuliconazoleThe serum concentration of Nortriptyline can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Nortriptyline can be decreased when it is combined with Lumacaftor.
LumefantrineNortriptyline may increase the QTc-prolonging activities of Lumefantrine.
LumefantrineThe metabolism of Nortriptyline can be decreased when combined with Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Maprotiline.
MebanazineMebanazine may increase the serotonergic activities of Nortriptyline.
MeclizineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Nortriptyline.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Nortriptyline.
MelperoneThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Melperone.
MephentermineNortriptyline may increase the stimulatory activities of Mephentermine.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Nortriptyline.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Nortriptyline.
MesoridazineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Mesoridazine.
MetaraminolNortriptyline may increase the vasopressor activities of Metaraminol.
MetaxaloneThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Metaxalone.
MethadoneNortriptyline may increase the QTc-prolonging activities of Methadone.
MethadoneThe metabolism of Nortriptyline can be decreased when combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Nortriptyline.
MethamphetamineNortriptyline may increase the stimulatory activities of Methamphetamine.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Nortriptyline.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Nortriptyline.
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Nortriptyline.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Nortriptyline.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Methotrimeprazine.
MethoxamineNortriptyline may increase the vasopressor activities of Methoxamine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Nortriptyline.
MethsuximideThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Methsuximide.
Methylene blueNortriptyline may increase the serotonergic activities of Methylene blue.
MethylphenidateThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Nortriptyline.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Nortriptyline.
MetoclopramideThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Metoclopramide.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Nortriptyline.
MetoprololThe metabolism of Nortriptyline can be decreased when combined with Metoprolol.
MetyrosineNortriptyline may increase the sedative activities of Metyrosine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Nortriptyline.
MexiletineThe metabolism of Nortriptyline can be decreased when combined with Mexiletine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Nortriptyline.
MidodrineNortriptyline may increase the vasopressor activities of Midodrine.
MifepristoneThe metabolism of Nortriptyline can be decreased when combined with Mifepristone.
MifepristoneNortriptyline may increase the QTc-prolonging activities of Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Milnacipran.
MinaprineMinaprine may increase the serotonergic activities of Nortriptyline.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.
MirabegronThe metabolism of Nortriptyline can be decreased when combined with Mirabegron.
MirtazapineNortriptyline may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Nortriptyline.
MitotaneThe serum concentration of Nortriptyline can be decreased when it is combined with Mitotane.
MoclobemideMoclobemide may increase the serotonergic activities of Nortriptyline.
MoclobemideThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Moclobemide.
ModafinilThe serum concentration of Nortriptyline can be decreased when it is combined with Modafinil.
MoexiprilThe serum concentration of Nortriptyline can be increased when it is combined with Moexipril.
MolindoneThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Molindone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Nortriptyline.
MoxifloxacinNortriptyline may increase the QTc-prolonging activities of Moxifloxacin.
MoxonidineThe therapeutic efficacy of Moxonidine can be decreased when used in combination with Nortriptyline.
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Nortriptyline can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.
NabiloneThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Nabilone.
NafcillinThe serum concentration of Nortriptyline can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Nortriptyline.
NaphazolineThe therapeutic efficacy of Naphazoline can be decreased when used in combination with Nortriptyline.
NaratriptanThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Naratriptan.
NCX 4016The serum concentration of Nortriptyline can be increased when it is combined with NCX 4016.
NefazodoneThe metabolism of Nortriptyline can be decreased when combined with Nefazodone.
NefazodoneThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Nefazodone.
NelfinavirThe serum concentration of Nortriptyline can be increased when it is combined with Nelfinavir.
NetupitantThe serum concentration of Nortriptyline can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Nortriptyline can be decreased when combined with Nevirapine.
NialamideNialamide may increase the serotonergic activities of Nortriptyline.
NicardipineThe metabolism of Nortriptyline can be decreased when combined with Nicardipine.
NicorandilNortriptyline may increase the hypotensive activities of Nicorandil.
NilotinibThe metabolism of Nortriptyline can be decreased when combined with Nilotinib.
NilotinibNortriptyline may increase the QTc-prolonging activities of Nilotinib.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Nortriptyline.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Nortriptyline.
NorepinephrineThe therapeutic efficacy of Norepinephrine can be decreased when used in combination with Nortriptyline.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Nortriptyline.
OctamoxinOctamoxin may increase the serotonergic activities of Nortriptyline.
OfloxacinNortriptyline may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Olanzapine.
OlaparibThe metabolism of Nortriptyline can be decreased when combined with Olaparib.
OlodaterolThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Olodaterol.
OlopatadineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Olopatadine.
OmapatrilatThe serum concentration of Nortriptyline can be increased when it is combined with Omapatrilat.
OmeprazoleThe metabolism of Nortriptyline can be decreased when combined with Omeprazole.
OndansetronThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Ondansetron.
OndansetronOndansetron may increase the serotonergic activities of Nortriptyline.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Nortriptyline.
OrciprenalineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Orciprenaline.
OrphenadrineNortriptyline may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Nortriptyline.
OsanetantThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Osanetant.
OsimertinibThe serum concentration of Nortriptyline can be increased when it is combined with Osimertinib.
OtamixabanThe serum concentration of Nortriptyline can be increased when it is combined with Otamixaban.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Nortriptyline.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Nortriptyline.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Nortriptyline.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Nortriptyline.
OxymetazolineThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Nortriptyline.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Nortriptyline.
PalbociclibThe serum concentration of Nortriptyline can be increased when it is combined with Palbociclib.
PaliperidoneThe therapeutic efficacy of Paliperidone can be decreased when used in combination with Nortriptyline.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Nortriptyline.
PalonosetronPalonosetron may increase the serotonergic activities of Nortriptyline.
PanobinostatNortriptyline may increase the QTc-prolonging activities of Panobinostat.
PanobinostatThe metabolism of Nortriptyline can be decreased when combined with Panobinostat.
PantoprazoleThe metabolism of Nortriptyline can be decreased when combined with Pantoprazole.
ParaldehydeNortriptyline may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Nortriptyline.
PargylinePargyline may increase the serotonergic activities of Nortriptyline.
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Nortriptyline.
PazopanibNortriptyline may increase the QTc-prolonging activities of Pazopanib.
Peginterferon alfa-2bThe serum concentration of Nortriptyline can be decreased when it is combined with Peginterferon alfa-2b.
PentamidineNortriptyline may increase the QTc-prolonging activities of Pentamidine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Nortriptyline.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Nortriptyline.
PerampanelThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Perampanel.
PerflutrenNortriptyline may increase the QTc-prolonging activities of Perflutren.
PergolideThe therapeutic efficacy of Pergolide can be decreased when used in combination with Nortriptyline.
PerindoprilThe serum concentration of Nortriptyline can be increased when it is combined with Perindopril.
PerospironeThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Nortriptyline.
PhenelzinePhenelzine may increase the serotonergic activities of Nortriptyline.
PhenelzineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Phenelzine.
PhenindioneNortriptyline may increase the anticoagulant activities of Phenindione.
PheniprazinePheniprazine may increase the serotonergic activities of Nortriptyline.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Nortriptyline.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Nortriptyline.
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Nortriptyline.
PhenprocoumonNortriptyline may increase the anticoagulant activities of Phenprocoumon.
PhentermineNortriptyline may increase the stimulatory activities of Phentermine.
PhenylephrineNortriptyline may increase the vasopressor activities of Phenylephrine.
PhenylpropanolamineThe therapeutic efficacy of Phenylpropanolamine can be decreased when used in combination with Nortriptyline.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Nortriptyline.
PhosphoramidonThe serum concentration of Nortriptyline can be increased when it is combined with Phosphoramidon.
PimozideThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Pimozide.
PipamperoneThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Pipotiazine.
PirbuterolThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Pirbuterol.
PirlindolePirlindole may increase the serotonergic activities of Nortriptyline.
PivhydrazinePivhydrazine may increase the serotonergic activities of Nortriptyline.
PizotifenThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Pomalidomide.
PosaconazoleThe metabolism of Nortriptyline can be decreased when combined with Posaconazole.
PramipexoleNortriptyline may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Nortriptyline.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Nortriptyline.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Nortriptyline.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Nortriptyline.
PrimaquineNortriptyline may increase the QTc-prolonging activities of Primaquine.
PrimidoneThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Primidone.
PrinomastatThe serum concentration of Nortriptyline can be increased when it is combined with Prinomastat.
ProcainamideNortriptyline may increase the QTc-prolonging activities of Procainamide.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Nortriptyline.
ProcarbazineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Procarbazine.
ProcaterolThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Procaterol.
ProchlorperazineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Prochlorperazine.
PromazineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Promazine.
PromazineThe metabolism of Nortriptyline can be decreased when combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Promethazine.
PropafenoneNortriptyline may increase the QTc-prolonging activities of Propafenone.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Nortriptyline.
PropericiazineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Propericiazine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Nortriptyline.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Nortriptyline.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Nortriptyline.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Nortriptyline.
PseudoephedrineThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Nortriptyline.
PyrimethamineThe metabolism of Nortriptyline can be decreased when combined with Pyrimethamine.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Nortriptyline.
QuetiapineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Quetiapine.
QuinaprilThe serum concentration of Nortriptyline can be increased when it is combined with Quinapril.
QuinidineNortriptyline may increase the QTc-prolonging activities of Quinidine.
QuinidineThe metabolism of Nortriptyline can be decreased when combined with Quinidine.
QuinineNortriptyline may increase the QTc-prolonging activities of Quinine.
QuinineThe metabolism of Nortriptyline can be decreased when combined with Quinine.
RamelteonThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Ramelteon.
RamiprilThe serum concentration of Nortriptyline can be increased when it is combined with Ramipril.
RanolazineThe metabolism of Nortriptyline can be decreased when combined with Ranolazine.
RasagilineRasagiline may increase the serotonergic activities of Nortriptyline.
RasagilineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Rasagiline.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Nortriptyline.
RemikirenThe serum concentration of Nortriptyline can be increased when it is combined with Remikiren.
RemoxiprideThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Remoxipride.
ReserpineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Reserpine.
RifabutinThe metabolism of Nortriptyline can be increased when combined with Rifabutin.
RifampicinThe metabolism of Nortriptyline can be increased when combined with Rifampicin.
RifapentineThe metabolism of Nortriptyline can be increased when combined with Rifapentine.
RisperidoneThe therapeutic efficacy of Risperidone can be decreased when used in combination with Nortriptyline.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Nortriptyline.
RitodrineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Ritodrine.
RitonavirThe serum concentration of Nortriptyline can be increased when it is combined with Ritonavir.
RivaroxabanThe serum concentration of Nortriptyline can be increased when it is combined with Rivaroxaban.
RizatriptanThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Rizatriptan.
RolapitantThe metabolism of Nortriptyline can be decreased when combined with Rolapitant.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Nortriptyline.
RopiniroleNortriptyline may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Nortriptyline can be decreased when combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Nortriptyline.
RotigotineNortriptyline may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Nortriptyline.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Nortriptyline.
SafrazineSafrazine may increase the serotonergic activities of Nortriptyline.
SalbutamolThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Salbutamol.
SalmeterolThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Salmeterol.
SaquinavirThe serum concentration of Nortriptyline can be increased when it is combined with Saquinavir.
SaquinavirNortriptyline may increase the QTc-prolonging activities of Saquinavir.
SaxagliptinThe serum concentration of Nortriptyline can be increased when it is combined with Saxagliptin.
ScopolamineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Nortriptyline.
SelegilineSelegiline may increase the serotonergic activities of Nortriptyline.
SelegilineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Selegiline.
SertindoleThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Sertraline.
SertralineThe metabolism of Nortriptyline can be decreased when combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Nortriptyline.
SildenafilThe metabolism of Nortriptyline can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Nortriptyline can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Nortriptyline can be increased when it is combined with Simeprevir.
SitagliptinThe serum concentration of Nortriptyline can be increased when it is combined with Sitagliptin.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Nortriptyline.
SorafenibThe metabolism of Nortriptyline can be decreased when combined with Sorafenib.
SotalolNortriptyline may increase the QTc-prolonging activities of Sotalol.
SpiraprilThe serum concentration of Nortriptyline can be increased when it is combined with Spirapril.
St. John's WortThe serum concentration of Nortriptyline can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Nortriptyline.
SulfadiazineThe metabolism of Nortriptyline can be decreased when combined with Sulfadiazine.
SulfamethoxazoleThe metabolism of Nortriptyline can be decreased when combined with Sulfamethoxazole.
SulfisoxazoleNortriptyline may increase the QTc-prolonging activities of Sulfisoxazole.
SulfisoxazoleThe metabolism of Nortriptyline can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Sumatriptan.
SuvorexantThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Tasimelteon.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Nortriptyline.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Tedizolid Phosphate.
TelaprevirThe serum concentration of Nortriptyline can be increased when it is combined with Telaprevir.
TelavancinNortriptyline may increase the QTc-prolonging activities of Telavancin.
TelithromycinNortriptyline may increase the QTc-prolonging activities of Telithromycin.
TelithromycinThe metabolism of Nortriptyline can be decreased when combined with Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Nortriptyline.
TemocaprilThe serum concentration of Nortriptyline can be increased when it is combined with Temocapril.
TenofovirThe metabolism of Nortriptyline can be decreased when combined with Tenofovir.
TerbinafineThe metabolism of Nortriptyline can be decreased when combined with Terbinafine.
TerbutalineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Terbutaline.
TeriflunomideThe serum concentration of Nortriptyline can be decreased when it is combined with Teriflunomide.
TetrabenazineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Nortriptyline.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Nortriptyline.
ThalidomideNortriptyline may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Nortriptyline.
TheophyllineThe metabolism of Nortriptyline can be decreased when combined with Theophylline.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Nortriptyline.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Nortriptyline.
ThioproperazineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Thioproperazine.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Nortriptyline.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Nortriptyline.
ThiorphanThe serum concentration of Nortriptyline can be increased when it is combined with Thiorphan.
ThiothixeneThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Thiothixene.
Thyroid, porcineThyroid, porcine may increase the arrhythmogenic activities of Nortriptyline.
TiagabineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Tiagabine.
TicagrelorThe metabolism of Nortriptyline can be decreased when combined with Ticagrelor.
TiclopidineThe metabolism of Nortriptyline can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Nortriptyline.
TipranavirThe serum concentration of Nortriptyline can be increased when it is combined with Tipranavir.
TizanidineThe therapeutic efficacy of Tizanidine can be decreased when used in combination with Nortriptyline.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Nortriptyline.
TocilizumabThe serum concentration of Nortriptyline can be decreased when it is combined with Tocilizumab.
TolbutamideThe metabolism of Nortriptyline can be decreased when combined with Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Nortriptyline.
ToloxatoneToloxatone may increase the serotonergic activities of Nortriptyline.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Nortriptyline.
ToremifeneNortriptyline may increase the QTc-prolonging activities of Toremifene.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Nortriptyline.
TrandolaprilThe serum concentration of Nortriptyline can be increased when it is combined with Trandolapril.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Nortriptyline.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineTranylcypromine may increase the serotonergic activities of Nortriptyline.
TranylcypromineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Tranylcypromine.
TrazodoneThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Nortriptyline.
TrifluoperazineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Triflupromazine.
TrimethoprimThe metabolism of Nortriptyline can be decreased when combined with Trimethoprim.
TrimipramineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Nortriptyline.
UbenimexThe serum concentration of Nortriptyline can be increased when it is combined with Ubenimex.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Nortriptyline.
ValsartanThe metabolism of Nortriptyline can be decreased when combined with Valsartan.
VandetanibNortriptyline may increase the QTc-prolonging activities of Vandetanib.
VemurafenibThe serum concentration of Nortriptyline can be increased when it is combined with Vemurafenib.
VemurafenibNortriptyline may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe metabolism of Nortriptyline can be decreased when combined with Venlafaxine.
VenlafaxineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Venlafaxine.
VerapamilThe metabolism of Nortriptyline can be decreased when combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Vigabatrin.
VilanterolThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Vilanterol.
VilazodoneThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Vilazodone.
VildagliptinThe serum concentration of Nortriptyline can be increased when it is combined with Vildagliptin.
VoriconazoleThe metabolism of Nortriptyline can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Vortioxetine.
WarfarinNortriptyline may increase the anticoagulant activities of Warfarin.
XimelagatranThe serum concentration of Nortriptyline can be increased when it is combined with Ximelagatran.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Nortriptyline.
XylometazolineThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Nortriptyline.
YohimbineThe serum concentration of Yohimbine can be increased when it is combined with Nortriptyline.
ZafirlukastThe metabolism of Nortriptyline can be decreased when combined with Zafirlukast.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Nortriptyline.
ZiconotideThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Ziprasidone.
ZiprasidoneThe metabolism of Nortriptyline can be decreased when combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Nortriptyline.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Nortriptyline.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Nortriptyline.
ZonisamideThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Nortriptyline.
ZotepineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Zuclopenthixol.
Food Interactions
  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (caffeine).
  • Take with food to reduce irritation.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Roubert C, Cox PJ, Bruss M, Hamon M, Bonisch H, Giros B: Determination of residues in the norepinephrine transporter that are critical for tricyclic antidepressant affinity. J Biol Chem. 2001 Mar 16;276(11):8254-60. Epub 2000 Nov 22. [PubMed:11092898 ]
  2. Roubert C, Sagne C, Kapsimali M, Vernier P, Bourrat F, Giros B: A Na(+)/Cl(-)-dependent transporter for catecholamines, identified as a norepinephrine transporter, is expressed in the brain of the teleost fish medaka (Oryzias latipes). Mol Pharmacol. 2001 Sep;60(3):462-73. [PubMed:11502876 ]
  3. Vaishnavi SN, Nemeroff CB, Plott SJ, Rao SG, Kranzler J, Owens MJ: Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry. 2004 Feb 1;55(3):320-2. [PubMed:14744476 ]
  4. Kim H, Lim SW, Kim S, Kim JW, Chang YH, Carroll BJ, Kim DK: Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression. JAMA. 2006 Oct 4;296(13):1609-18. [PubMed:17018806 ]
  5. Barker EL, Blakely RD: Identification of a single amino acid, phenylalanine 586, that is responsible for high affinity interactions of tricyclic antidepressants with the human serotonin transporter. Mol Pharmacol. 1996 Oct;50(4):957-65. [PubMed:8863842 ]
  6. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Joyce PR, Mulder RT, Luty SE, McKenzie JM, Miller AL, Rogers GR, Kennedy MA: Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline. Int J Neuropsychopharmacol. 2003 Dec;6(4):339-46. [PubMed:14604448 ]
  2. Wisner KL, Hanusa BH, Perel JM, Peindl KS, Piontek CM, Sit DK, Findling RL, Moses-Kolko EL: Postpartum depression: a randomized trial of sertraline versus nortriptyline. J Clin Psychopharmacol. 2006 Aug;26(4):353-60. [PubMed:16855451 ]
  3. Pollock BG, Ferrell RE, Mulsant BH, Mazumdar S, Miller M, Sweet RA, Davis S, Kirshner MA, Houck PR, Stack JA, Reynolds CF, Kupfer DJ: Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology. 2000 Nov;23(5):587-90. [PubMed:11027924 ]
  4. Vaishnavi SN, Nemeroff CB, Plott SJ, Rao SG, Kranzler J, Owens MJ: Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry. 2004 Feb 1;55(3):320-2. [PubMed:14744476 ]
  5. Rausch JL, Moeller FG, Johnson ME: Initial platelet serotonin (5-HT) transport kinetics predict nortriptyline treatment outcome. J Clin Psychopharmacol. 2003 Apr;23(2):138-44. [PubMed:12640215 ]
  6. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
  2. Sadava D, Wilmington K: Tricyclic antidepressant drugs affect histamine receptors in human leukocytes. Life Sci. 1984 Dec 17;35(25):2545-8. [PubMed:6096660 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
  2. Nojimoto FD, Mueller A, Hebeler-Barbosa F, Akinaga J, Lima V, Kiguti LR, Pupo AS: The tricyclic antidepressants amitriptyline, nortriptyline and imipramine are weak antagonists of human and rat alpha1B-adrenoceptors. Neuropharmacology. 2010 Jul-Aug;59(1-2):49-57. doi: 10.1016/j.neuropharm.2010.03.015. Epub 2010 Apr 2. [PubMed:20363235 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Alpha1-adrenergic receptor activity
Specific Function:
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name:
ADRA1D
Uniprot ID:
P25100
Molecular Weight:
60462.205 Da
References
  1. Nojimoto FD, Mueller A, Hebeler-Barbosa F, Akinaga J, Lima V, Kiguti LR, Pupo AS: The tricyclic antidepressants amitriptyline, nortriptyline and imipramine are weak antagonists of human and rat alpha1B-adrenoceptors. Neuropharmacology. 2010 Jul-Aug;59(1-2):49-57. doi: 10.1016/j.neuropharm.2010.03.015. Epub 2010 Apr 2. [PubMed:20363235 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.
Gene Name:
CHRM4
Uniprot ID:
P08173
Molecular Weight:
53048.65 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM5
Uniprot ID:
P08912
Molecular Weight:
60073.205 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Palvimaki EP, Roth BL, Majasuo H, Laakso A, Kuoppamaki M, Syvalahti E, Hietala J: Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor. Psychopharmacology (Berl). 1996 Aug;126(3):234-40. [PubMed:8876023 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase. It has a high affinity for tricyclic psychotropic drugs (By similarity). Controls pyramidal neurons migration during corticogenesis, through...
Gene Name:
HTR6
Uniprot ID:
P50406
Molecular Weight:
46953.625 Da
References
  1. Monsma FJ Jr, Shen Y, Ward RP, Hamblin MW, Sibley DR: Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol. 1993 Mar;43(3):320-7. [PubMed:7680751 ]
  2. Goodman, Louis Sanford;Brunton, Laurence L.;Chabner, Bruce;Knollman, Bjorn (2011). The Pharmacological Basis of Therapeutics (12th ed.). McGraw-Hill Professional Publishing. [ISBN:978-0-07-162442-8 ]
  3. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Nojimoto FD, Mueller A, Hebeler-Barbosa F, Akinaga J, Lima V, Kiguti LR, Pupo AS: The tricyclic antidepressants amitriptyline, nortriptyline and imipramine are weak antagonists of human and rat alpha1B-adrenoceptors. Neuropharmacology. 2010 Jul-Aug;59(1-2):49-57. doi: 10.1016/j.neuropharm.2010.03.015. Epub 2010 Apr 2. [PubMed:20363235 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianserine > chlorpromazine = spiperone = prazosin > propanolol > alprenolol = pindolol.
Components:
NameUniProt IDDetails
Alpha-2A adrenergic receptorP08913 Details
Alpha-2B adrenergic receptorP18089 Details
Alpha-2C adrenergic receptorP18825 Details
References
  1. Goodman, Louis Sanford;Brunton, Laurence L.;Chabner, Bruce;Knollman, Bjorn (2011). The Pharmacological Basis of Therapeutics (12th ed.). McGraw-Hill Professional Publishing. [ISBN:978-0-07-162442-8 ]
  2. PDSP Ki Database [Link]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Components:
NameUniProt IDDetails
Beta-1 adrenergic receptorP08588 Details
Beta-2 adrenergic receptorP07550 Details
Beta-3 adrenergic receptorP13945 Details
References
  1. Goodman, Louis Sanford;Brunton, Laurence L.;Chabner, Bruce;Knollman, Bjorn (2011). The Pharmacological Basis of Therapeutics (12th ed.). McGraw-Hill Professional Publishing. [ISBN:978-0-07-162442-8 ]
  2. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Peroutka SJ, Snyder SH: Antiemetics: neurotransmitter receptor binding predicts therapeutic actions. Lancet. 1982 Mar 20;1(8273):658-9. [PubMed:6121969 ]
  2. Goodman, Louis Sanford;Brunton, Laurence L.;Chabner, Bruce;Knollman, Bjorn (2011). The Pharmacological Basis of Therapeutics (12th ed.). McGraw-Hill Professional Publishing. [ISBN:978-0-07-162442-8 ]
  3. PDSP Ki Database [Link]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Steroid binding
Specific Function:
Receptor for progesterone.
Components:
NameUniProt IDDetails
Membrane-associated progesterone receptor component 1O00264 Details
Sigma non-opioid intracellular receptor 1Q99720 Details
References
  1. Goodman, Louis Sanford;Brunton, Laurence L.;Chabner, Bruce;Knollman, Bjorn (2011). The Pharmacological Basis of Therapeutics (12th ed.). McGraw-Hill Professional Publishing. [ISBN:978-0-07-162442-8 ]
  2. PDSP Ki Database [Link]
Kind
Protein
Organism
Rat
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
Htr2c
Uniprot ID:
P08909
Molecular Weight:
51916.005 Da
References
  1. Jenck F, Moreau JL, Mutel V, Martin JR, Haefely WE: Evidence for a role of 5-HT1C receptors in the antiserotonergic properties of some antidepressant drugs. Eur J Pharmacol. 1993 Feb 9;231(2):223-9. [PubMed:8453978 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Wen B, Ma L, Zhu M: Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s. Chem Biol Interact. 2008 May 9;173(1):59-67. doi: 10.1016/j.cbi.2008.02.001. Epub 2008 Feb 14. [PubMed:18359012 ]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  4. Venkatakrishnan K, von Moltke LL, Greenblatt DJ: Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): implications for interactions with enzyme-inducing drugs. J Clin Pharmacol. 1999 Jun;39(6):567-77. [PubMed:10354960 ]
  5. Olesen OV, Linnet K: Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA-expressed human cytochrome P-450 isozymes. Drug Metab Dispos. 1997 Jun;25(6):740-4. [PubMed:9193876 ]
  6. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Wen B, Ma L, Zhu M: Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s. Chem Biol Interact. 2008 May 9;173(1):59-67. doi: 10.1016/j.cbi.2008.02.001. Epub 2008 Feb 14. [PubMed:18359012 ]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  4. Venkatakrishnan K, von Moltke LL, Greenblatt DJ: Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): implications for interactions with enzyme-inducing drugs. J Clin Pharmacol. 1999 Jun;39(6):567-77. [PubMed:10354960 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Wen B, Ma L, Zhu M: Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s. Chem Biol Interact. 2008 May 9;173(1):59-67. doi: 10.1016/j.cbi.2008.02.001. Epub 2008 Feb 14. [PubMed:18359012 ]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  4. Olesen OV, Linnet K: Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA-expressed human cytochrome P-450 isozymes. Drug Metab Dispos. 1997 Jun;25(6):740-4. [PubMed:9193876 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Olesen OV, Linnet K: Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA-expressed human cytochrome P-450 isozymes. Drug Metab Dispos. 1997 Jun;25(6):740-4. [PubMed:9193876 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Wen B, Ma L, Zhu M: Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s. Chem Biol Interact. 2008 May 9;173(1):59-67. doi: 10.1016/j.cbi.2008.02.001. Epub 2008 Feb 14. [PubMed:18359012 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
no
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Brinkschulte M, Breyer-Pfaff U: The contribution of alpha 1-acid glycoprotein, lipoproteins, and albumin to the plasma binding of perazine, amitriptyline, and nortriptyline in healthy man. Naunyn Schmiedebergs Arch Pharmacol. 1980 Oct;314(1):61-6. [PubMed:6108517 ]
Kind
Protein
Organism
Human
Pharmacological action
no
General Function:
Not Available
Specific Function:
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in the body. Appears to function in modulating the activity of the immune system during the acute-phase reaction.
Gene Name:
ORM1
Uniprot ID:
P02763
Molecular Weight:
23511.38 Da
References
  1. Brinkschulte M, Breyer-Pfaff U: The contribution of alpha 1-acid glycoprotein, lipoproteins, and albumin to the plasma binding of perazine, amitriptyline, and nortriptyline in healthy man. Naunyn Schmiedebergs Arch Pharmacol. 1980 Oct;314(1):61-6. [PubMed:6108517 ]
  2. Ferry DG, Caplan NB, Cubeddu LX: Interaction between antidepressants and alpha 1-adrenergic receptor antagonists on the binding to alpha 1-acid glycoprotein. J Pharm Sci. 1986 Feb;75(2):146-9. [PubMed:2870173 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23